South San Francisco, CA May 17, 2018 by Heather Hefner, Fifth Grade Teacher, Sunshine Garden Elementary, South San Francisco Rebroadcasted from Genentech Once a week, when school lets out at Sunshine Garden Elementary in South San Francisco, a group of…
Tag: Genentech
Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
South San Francisco, CA April 16, 2018 Genentech Press Release Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker…
DA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
South San Francisco, CA March 22, 2018 Genentech Press Release First and only prefilled syringe treatment option FDA-approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME) Diabetic retinopathy is the leading…
Can We Make Quality of Life a Priority in SSF?
South San Francisco, CA March 9, 2018 by Mel Ellison, ESC Correspondent Like the rumbling of a jet on takeoff from SFO, the sound of discontent can be heard throughout South San Francisco, but are our City officials listening? The…
Phase III IMpower150 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer
South San Francisco, CA November 29, 2017 Genentech Press Release – Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) – SOUTH SAN FRANCISCO, CA — 2017-11-19 00:00:00 Genentech,…
Genentech’s Hemlibra (Emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A
South San Francisco, CA November 29, 2017 Genentech Press Release HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison demonstrated superiority of HEMLIBRA prophylaxis compared to prior factor VIII prophylaxis SOUTH SAN FRANCISCO, CA — 2017-11-19 00:00:00…
FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
South San Francisco, CA November 16, 2017 Genentech Press Release The first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the…
FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A with Inhibitors
South San Francisco, CA November 16, 2017 Genentech Press Release First new medicine in nearly 20 years to treat people with hemophilia A with inhibitors HEMLIBRA substantially reduced bleeds in adults and children Only medicine that can be…
FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
South San Francisco, CA November 6, 2017 Genentech Press Release — Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease — — Approval based on data from a basket study, which enrolls participants across…
May 2017 Development Activity List for the City Of South San Francisco
South San Francisco, CA October 27, 2017 from City Website NOTE: FOR MORE ESC INFO ON THE BUILDING IN SSF PLEASE CLICK HERE OFFICE/ R&D PROJECTS IN SOUTH SAN FRANCISCO